

## Erratum

# Erratum to ‘In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome’ [Int. J. Pharm. 203 (2000) 61–69]<sup>☆</sup>

Wang Junping, Yoshie Maitani \*, Kozo Takayama, Tsuneji Nagai

*Department of Pharmaceutics, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo 142-8501, Japan*

---

The publisher regrets that in the above article the symbols that appeared in Figs. 2, 4 and 5 were incorrectly defined in the figure legends. The figures and their corrected figure legends are reproduced overleaf.

<sup>☆</sup> PII of original article: S0378-5173(00)00410-5.

\* Corresponding author. Tel.: + 81-3-54985782; fax: + 81-3-54985782.

*E-mail address:* yoshie@hoshi.ac.jp (Y. Maitani).




Fig. 2. Drug levels in heart tissue after i.v. injection of doxorubicin (DXR) of different formulations into C57BL/6 mice at a dose of 5 mg DXR/kg. ●, LRP-L-DXR; ○, CL-DXR; ▲, F-DXR. Results are given as means ± S.D., n = 3.




Fig. 5. Drug levels in kidney tissue after i.v. injection of doxorubicin (DXR) of different formulations into C57BL/6 mice at a dose of 5 mg DXR/kg. ●, LRP-L-DXR; ○, CL-DXR; ▲, F-DXR. Results are given as means ± S.D., n = 3.




Fig. 4. Drug levels in spleen tissue after i.v. injection of doxorubicin (DXR) of different formulations into C57BL/6 mice at a dose of 5 mg DXR/kg. ●, LRP-L-DXR; ○, CL-DXR; ▲, F-DXR. Results are given as means ± S.D., n = 3.